Details for Patent: 8,562,952

Title:	Methods for manipulating satiety
Abstract:	Various embodiments of the invention disclosed herein include methods of inducing satiety a mammal in need thereof. Also disclosed are methods of inducing satiety in an obese mammal. Additionally disclose are method of suppressing appetite in a mammal in need thereof. Further disclosed are methods of treating obesity. The methods described herein involve the administration of serotonin, a serotonin agonist or a serotonin re-uptake inhibitor to the mammal.
Inventor(s):	Lin; Henry C. (Albuquerque, NM)
Assignee:	Cedars-Sinai Medical Center (Los Angeles, CA)
Filing Date:	Mar 01, 2013
Application Number:	13/782,504
Claims:	1. A method of weight management in a mammal in need thereof, comprising: providing a composition comprising a serotonin receptor agonist, and a pharmaceutically acceptable carrier or an excipient; and administering the composition to the mammal, whereby weight loss is induced in the mammal by the serotonin receptor agonist activating, in the gastrointestinal tract, the cholinergic intestino-fugal pathway, at least one prevertebral ganglionic pathway, the adrenergic efferent neural pathway, the serotonergic interneuron and/or the opioid interneuron. 2. The method of claim 1, wherein administering is via oral delivery. 3. The method of claim 1, wherein administering is via enteral delivery. 4. The method of claim 1, wherein the mammal is human. 5. The method of claim 1, wherein the mammal is obese. 6. The method of claim 1, wherein the mammal is an obese human. 7. The method of claim 1, wherein the composition is in a coated tablet. 8. A method of inducing satiety in a mammal in need thereof, comprising: providing a composition comprising a serotonin receptor agonist, and a pharmaceutically acceptable carrier or an excipient; and administering the composition to the mammal, whereby a state of satiety is induced in the mammal by the serotonin receptor agonist activating, in the gastrointestinal tract, the cholinergic intestino-fugal pathway, at least one prevertebral ganglionic pathway, the adrenergic efferent neural pathway, the serotonergic interneuron and/or the opioid interneuron. 9. The method of claim 8, wherein administering is via oral delivery. 10. The method of claim 8, wherein administering is via enteral delivery. 11. The method of claim 8, wherein the mammal is human. 12. The method of claim 8, wherein the mammal is obese. 13. The method of claim 8, wherein the mammal is an obese human. 14. The method of claim 8, wherein the composition is in a coated tablet. 15. A method of suppressing appetite in a mammal in need thereof, comprising: providing a serotonin receptor agonist; and administering the serotonin receptor agonist to the mammal, whereby the appetite is suppressed in the mammal by the serotonin receptor agonist activating, in the gastrointestinal tract, the cholinergic intestino-fugal pathway, at least one prevertebral ganglionic pathway, the adrenergic efferent neural pathway, the serotonergic interneuron and/or the opioid interneuron. 16. The method of claim 15, wherein administering is via oral delivery. 17. The method of claim 15, wherein administering is via enteral delivery. 18. The method of claim 15, wherein the mammal is an obese mammal. 19. The method of claim 15, wherein the mammal is human. 20. The method of claim 15, wherein the mammal is an obese human. 21. The method of claim 15, wherein the composition is in a coated tablet. 22. A method of treating obesity in a mammal in need thereof, comprising: providing a serotonin receptor agonist; and administering the serotonin receptor agonist to the mammal, whereby obesity is treated in the mammal by the serotonin receptor agonist activating, in the gastrointestinal tract, the cholinergic intestino-fugal pathway, at least one prevertebral ganglionic pathway, the adrenergic efferent neural pathway, the serotonergic interneuron and/or the opioid interneuron. 23. The method of claim 22, wherein administering is via oral delivery. 24. The method of claim 22, wherein administering is via enteral delivery. 25. The method of claim 22, wherein the mammal is human. 26. The method of claim 22, wherein the composition is in a coated tablet.